- Home
- PCF vs ATRA Comparison
PCF vs ATRA Comparison
Compare PCF & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCF | ATRA |
|---|---|---|
| Founded | 1987 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.4M | 99.1M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | PCF | ATRA |
|---|---|---|
| Price | $6.11 | $18.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | ★ 74.8K | 71.6K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 10.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.97 |
| Revenue | N/A | ★ $151,930,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.15 |
| Revenue Growth | N/A | ★ 51.27 |
| 52 Week Low | $5.71 | $5.01 |
| 52 Week High | $6.96 | $18.71 |
Technical Indicators
Market Signals| Indicator | PCF | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 34.76 | 69.17 |
| Support Level | $6.23 | $14.37 |
| Resistance Level | $6.28 | $18.37 |
| Average True Range (ATR) | 0.04 | 1.19 |
| MACD | -0.00 | 0.49 |
| Stochastic Oscillator | 10.53 | 94.07 |
Price Performance
Historical ComparisonAbout PCF High Income Securities Fund
High Income Securities Fund is a closed-end management investment company. Its primary objective is to provide high current income and capital appreciation is the secondary objective. The Fund pursues its objective mainly by investing in both convertible bonds and convertible preferred stocks. The Fund also invests significantly in high-yielding non-convertible securities with the potential for capital appreciation.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).